Kuchma N. How single nucleotide gene polymorphism C677T metylentetrahidrofolat reductase and homocysteine content of the course and efficiency of treatment of nonalcoholic fatty liver disease combined with diabetes type 2.

The object of study: non-alcoholic fatty liver disease (NAFLD) in combination with diabetes mellitus (DM) type 2. Objective: to improve the efficiency of treatment of patients with NAFLD combined with DM type 2 by correcting hyperhomocysteinemia, depending on the C677T polymorphism of methylenetetrahydrofolate reductase (MTHFR) gene. Methods: clinical, anthropometric, laboratory (blood count, total cholesterol, triacylglycerides, cholesterol, low density lipoprotein, cholesterol HDL, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gammaglutamintranspeptidaza, total bilirubin), instrumental (ultrasound diagnostics), health and genetic (determination of genotypes of C677T and A1298C polymorphisms of the gene MTHFR, A66G methionine synthase reductase (MTRR) gene polymorphism and polymorphism A2756G methionine synthase (MTR) gene using polymerase chain reaction (PCR) detection of results of hybridization fluorescent method in real time), statistics. Scientific novelty of of the results: to study the frequency of alleles and genotypes of the C677T and A1298C polymorphism of MTHFR gene, A66G gene polymorphism MTRR gene polymorphism A2756G and MTR in patients with NAFLD and its combination with DM type 2 . Established Association of T/T genotype methylenetetrahydrofolate reductase gene with hyperhomocysteinemia in patients with NAFLD and DM 2 type. It is proved that the use of folic acid and vitamin B12 increased the anti-inflammatory activity of the standard treatment by reducing the content of biochemical parameters, lipid profile normalization and reduction of clinical symptoms in patients with NAFLD and in combination with DM 2 type. It is proved that patients with NAFLD and in combination with DM 2 type with T/T genotype of the gene of MTHFR, requires a long-term treatment with folic acid and vitamin B12 for the correction of hyperhomocysteinemia.